Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply constraints weighed on third-quarter results.
The company now expects net sales to grow by 5-6% at constant exchange rates, from mid-to-high-single-digit growth expected previously, and sees its core EBITDA margin reaching 23%-23.5% in 2026 compared with the previously forecast increase of around 100 basis points from the 21.7% recorded in 2025.
Third-quarter net sales of $2.94 billion missed the $3.01 billion analysts had expected in a Vara research-compiled consensus
Particularly its biosimilars unit slightly fell short of expectations with net sales reaching $998 million, a 17% jump at constant exchange rates compared with the same period last year, but below the $1.02 billion analysts had forecast
At its capital markets day in September, Sandoz had outlined steep mid-term growth, aiming to more than double annual net sales by 2035 and increase its biosimilars portfolio to 100 drugs by 2040 from 13
After expanding its biosimilars business in Europe, Sandoz said market conditions in Germany had proved more challenging than anticipated and that North America led the quarter's sales
No material contribution from the launch of generic semaglutide is expected this year, the company, which received approvals in Brazil and Canada in the diabetes and obesity drug market, said
Sandoz in March had filed an anti-dumping complaint with the European Commission against imports of Chinese amoxicillin APIs, the active pharmaceutical ingredient of the type of penicillin made by Sandoz, accusing makers of market distortion
(Reporting by Marleen Kaesebier in Zurich; Editing by Christian Schmollinger)
Copyright (2026) Thomson Reuters.
This article was from Reuters and was legally licensed through the DiveMarketplace by Industry Dive. Please direct all licensing questions to legal@industrydive.com.